Submit a Form



Submit a Form

Expand Content

Richard Ransohoff, MD


Richard Ransohoff, MD
Department: Neurosciences
Director, Neuroinflammation Research Center
Location: Cleveland Clinic Main Campus
Mail Code NC30
9500 Euclid Avenue
Cleveland, OH 44195
Richard Ransohoff, MD
Department: Neurology
Location: Cleveland Clinic Main Campus
Mail Code NC30
9500 Euclid Avenue
Cleveland, OH 44195
Richard Ransohoff, MD
Department: Mellen Center
Location: Cleveland Clinic Main Campus
Mail Code NC30
9500 Euclid Avenue
Cleveland, OH 44195
Both Adults and Children & Adolescents

Biographical Sketch

Richard M. Ransohoff, MD, is Director of the Neuroinflammation Research Center in the Department of Neurosciences of Lerner Research Institute, Cleveland Clinic; Professor of Molecular Medicine at the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University; and Staff Neurologist in the Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, Ohio. Dr. Ransohoff graduated with honors from Bard College, Annandale, N.Y., with a BA in literature, and received an MD degree with honors from Case Western Reserve University School of Medicine. He completed residencies in internal medicine at Mt. Sinai Medical Center in Cleveland (board-certified, 1981) and in neurology at Cleveland Clinic (board-certified, 1985). From 1984 until 1989, Dr. Ransohoff was a Postdoctoral Fellow in the laboratory of Dr. Timothy Nilsen in the Department of Molecular Biology and Microbiology at Case Western Reserve University School of Medicine.

Among other honors and awards, Dr. Ransohoff received a Physician’s Research Training Award from the American Cancer Society (1984-1986); a Harry Weaver Neuroscience Scholarship from the National Multiple Sclerosis Society (NMSS; 1987-1992); a Clinical Investigator Development Award from the National Institutes of Health (NIH; 1988-1993); the John and Samuel Bard Award in Science and Medicine (2002); the Cleveland Clinic Lerner Research Institute’s Award for Excellence in Science in 2006; the Scientific Achievement Award in Basic Science of the Cleveland Clinic (2009); the F.E. Bennett Lectureship of the American Neurological Association (2009). He has been cited continuously from 1996 through the present, in the “Best Doctors in America” for his expertise in the clinical care of patients with multiple sclerosis (MS). Dr. Ransohoff was elected to the American Association of Physicians in 2006 and as a Fellow of the American Association for the Advancement of Science (2007).

Dr. Ransohoff served as regular member on study sections of the NIH and NMSS (as Chair) and is currently a member of the CMBG Study Section (through 2016). He has served on the Editorial Boards of the Journal of Immunology (2002-2005 as Section Editor), Trends in Immunology, the Journal of Neuroimmunology, Nature Reviews Immunology, and Neurology (Associate Editor). From 1998-2000, Dr. Ransohoff was a member of the NINDS Director's Planning Panel on “The Neural Environment.” He is a member of the Steering Committee for the NIH Therapeutic Development Program in Spinal Muscular Atrophy; the Scientific Advisory Board for Chemocentryx, Mountain View, Calif and Vertex Pharmaceuticals (Cambridge, MA). He serves on External Advisory Boards for CHARTER (CNS HIV Anti-Retroviral Therapy Effects Research; MH22005); a Program Project on Alexander’s Disease (NS 42803); the MS Lesion Project (NMSS RG 3185; through 2008); the University of Nebraska’s Center for Neurovirology and Neurodegenerative Disorders (NS43985; through 2007) and was the External Advisor for the European Union’s Project on "Mechanisms of Brain Inflammation” (QLG3-00612; through 2005). He is a member of the National MS Society’s Medical Advisory Board. He was the Co-Director of the Marine Biological Laboratory’s special topics course on “Pathogenesis of Neuroimmunologic Disease” held biennially at Wood’s Hole, Mass (through 2008). He was a member of the External Advisory Board for Meharry Medical College’s Special Neuroscience Research Program (through 2008). He is a member of the Scientific Advisory Board of the Gladstone Institute for Neurological Disease, UCSF, San Francisco, CA.

Dr. Ransohoff’s research has focused on the functions of chemokines and chemokine receptors in development and pathology of the nervous system. He also has a longstanding interest in the mechanisms of action of interferon-beta. Dr. Ransohoff has received research support from the NIH and the NMSS continuously for more than 20 years. As of 2011, he lists more than 315 citations in PubMed, and has edited five books.

Dr. Ransohoff is a member of the American Academy of Neurology, the American Neurological Association, and the American Association of Physicians and the American Association for the Advancement of Science.

Dr. Ransohoff is married to Margaret Seidler Ransohoff. They have two daughters, Amy Julia and Lena Jane.

Professional Highlights

  • Lists more than 315 publications in PubMed as of  December 2011

Education & Fellowships

Residency - Cleveland Clinic
Cleveland, OH USA
Residency - Mount Sinai Medical Center (Closed)
Internal Medicine
Cleveland, OH USA
Medical School - Case Western Reserve University School of Medicine
Cleveland, OH USA
Undergraduate - Bard College
Annandale-on Hudson, NY USA


  • Neurology
  • Internal Medicine

Specialty Interests

Multiple Sclerosis, Neuroimmunology

Awards & Honors

  • Best Doctors, for expertise in care of patients with multiple sclerosis, from 1996-2012
  • Fellow, American Association for the Advancement of Science
  • Chair, Peer Review Committee B, National Multiple Sclerosis Society, 2003–2008
  • Co-Director, Marine Biological Labs Special Topics Course, "Pathogenesis of Neuroimmunological Disease," 2004–2008
  • Associate Editor, Neurology, 2006–date
  • Member, Editorial Advisory Board, Trends in Immunology, 2004–date
  • Member, Highlights Advisory Board, Nature Immunology Reviews, 2005–date
  • ANA/John Whitaker Visiting Professor, University of California/Irvine, 2008
  • Member, Scientific Advisory Board, Gladstone Institute for Neurological Disease, UCSF (2006-2012) 
  • Member, CMBG Study Section, NIH/CSR, 2010–2016
  • Member, Scientific Program Committee, American Neurological Association, 2010–2012
  • Presented yearly at Gordon and Keystone Conferences since 1994
  • Recent and Upcoming Lectureships:
    • Keynote Lecture, PACTRIMS, Bali, Indonesia, 2010
    • Invited Speaker, Keystone Symposium on Alzheimer’s disease, Copper Mtn, Co, 2010
    • Invited Speaker 20th Nikolas Symposium on Histiocytosis X, Athens, Greece, 2010
    • Invited Speaker, 7th Annual Johns Hopkins Symposium on MS, Washington, DC
    • Invited Speaker, FOCIS Symposium on Interventional Immunology, Boston, MA, 2010
    • Keynote Lecture, Neuroimmunology Symposium, Kyoto, Japan, 2010
    • Seminar, Theodor Kocher Institut, Bern, Switzerland, 2010–09–03
    • Invited Speaker and Session Chair, First Cell Press Symposium on “Inflammation and Disease”, Lisbon, Portugal, 2010
    • Plenary Session Speaker ICS/ISICR Annual Meeting, Session on Cytokine Therapy, Chicago, IL, 2010
    • Invited Speaker, Brazilian Society for Pharmacology, Ribeirao Prieto, Brazil, 2010
    • Invited Speaker, ISNI Biennial Meeting, Barcelona, Spain, 2010
    • McEwan Professorship in MS, University of Toronto, Canada, 2010

Additional Training

  • Postdoctoral Fellow, Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, 1984–1988

Innovations & Patents

  • U.S. Patent No. 6,414,118: beta-R1 chemokine
  • U.S. Patent No. 5,977,334: DNA encoding beta-R1 chemokine comprising the beta-R1 promoter


  • American Academy of Neurology
  • American Neurological Association
  • Fellow, American Association for the Advancement of Science
  • Association of American Physicians

Industry Relationships

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. The Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 2/11/2014, Dr. Ransohoff has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Consulting and/or Speaking. Dr. Ransohoff receives fees of $5,000 or more per year as a paid consultant, speaker or member of an advisory committee for the following companies:

  • Chemocentryx
  • Vertex Pharmaceuticals Incorporated

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.

Languages Spoken

  • English
  • French